New study confirms prebiotic efficacy of Clasado’s Bimuno GOS at ultra-low dose of just 380mg

Clasado Biosciences, a developer of prebiotic ingredients and products for the gut microbiome, has announced its Bimuno GOS shows a prebiotic effect at a low dose from just 380mg of active galactooligosaccharides (GOS) as uncovered in new pre-publication research.

The breakthrough research confirms that Bimuno GOS delivers a statistically significant prebiotic effect at an ultra-low dose, opening the door to new application opportunities for health and nutrition brands, the company said. This makes it a standout choice for product developers working with application formats as small as size 00 capsules, enabling the delivery of a proven prebiotic effect in a single low dose format, the company says. As the GOS with the lowest clinically supported dose of its kind for the general population, this latest development demonstrates exciting potential for the future, the company says.

Dr Lucien Harthoorn, R&D Director at Clasado Biosciences, said that this exciting new research demonstrates that even at remarkably low doses, Bimuno GOS continues to deliver its core prebiotic functionality. Harthoorn said that the study showed that at just 380mg of active GOS, there is still significant increases in beneficial bifidobacteria in the gut microbiome, the production of beneficial short-chain fatty acids (SCFAs), and lowering of intestinal pH – all key markers of prebiotic activity. Harthoorn hopes that the study will be published later in the year, and will provide more detailed findings on these exciting results.